In vitro anticancer activities and optical imaging of novel intercalative non-cisplatin conjugates

Journal of Medicinal Chemistry

Volumn 48, Issue 23, 2005, Pages 7192-7197

  Gao, Jian ^a,b   Woolley, F Ross ^a   Zingaro, Ralph A ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE; ANTHRAQUINONE; CISPLATIN; INTERCALATING AGENT; NAPHTHALENE DERIVATIVE; PLATINUM DERIVATIVE; SCHIFF BASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONFOCAL MICROSCOPY; DRUG EFFICACY; DRUG PENETRATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; OVARY CANCER; POLYMERIZATION;

ANTINEOPLASTIC AGENTS; AZA COMPOUNDS; CELL LINE, TUMOR; CHELATING AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCENT DYES; FLUOROMETRY; HUMANS; IMINES; INTERCALATING AGENTS; MICROSCOPY, CONFOCAL; ORGANOPLATINUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 28544453502     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050497t     Document Type: Article

References (34)

1. (a) Wong, E.; Giandomenico, C. M. Current Status of Platinum-Based Antitumor Drugs. Chem. Rev. 1999, 99, 2451-2466.
2. (b) Jamieson, E. R.; Lippard, S. J. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem. Rev. 1999, 99, 2467-2498.
3. (a) Najajreh, Y. Perez, J. M.; Navarro-Ranninger, C.; Gibson, D. Novel soluble cationic trans-diaminedichloroplatinum(II) complexes that are active against cisplatin resistant ovarian cancer cell lines. J. Med. Chem. 2002, 45, 5189-5198.
4. (b) Komeda, S.; Kalayda, G. V.; Lutz, M.; Spek, A. L.; Yamanaka, Y.; Sato, T.; Chikuma, M.; Reedijk, J. New isomeric azine-bridged dinuclear platinum(II) complexes circumvent cross-resistance to cisplatin. J. Med. Chem. 2003, 46, 1210-1219.
5. Zák, F.; Turánek, J.; Kroutil, A.; Sova, P.; Mistr, A.; Poulová, A.; Mikolin, P.; Zák, Z.; Kaná, Á.; Záluská, D.; Nea, J.; Sindlerová, L.; Kozubík, A. Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. J. Med Chem. 2004, 47, 761-763.
6. (a) Sundquist, W. I.; Bancroft, D. P.; Lippard, S. J. Synthesis, characterization, and biological activity of cis-diammineplatinum(II) complexes of the DNA intercalators 9-aminoacridine and chloroquine. J. Am Chem. Soc. 1990, 112, 1590-1596.
7. (b) Culliname, C.; Wickham, G.; MecFayden, W. D.; Denny, W. A.; Palmer, B. D.; Philips, D. R. The use of bidirectional transcription footprinting to detect platinum DNA cross-links by acridine-tethered platinum diamine complexes and cisplatin. Nucleic Acids Res. 1993, 21, 393-400.
8. Martins, E. T.; Baruah, H.; Kramarczyk, J.; Saluta, G.; Day, C. S.; Kucera, G. L.; Bierbach, U. Design, Synthesis, and Biological Activity of a Novel Non-Cisplatin-type Platinum-Acridine Pharmacophore. J. Med. Chem. 2001, 44, 4492-4496.
9. (a) Murray, V.; Motyka, H.; England, P. R.; Wickham, G.; Lee, H. H.; Denny, W. A.; Mcfayden, W. D. An investigation of the sequence-specific interaction of cis-diamminedichloroplatinum-(II) and four analogs, including two acridine-tethered complexes with DNA inside human cells. Biochemistry 1992, 31, 11812-11817.
10. (b) Murray, V.; Motyka, H.; England, P. R.; Wickham, G.; Lee, H. H.; Denny, W. A.; Mcfayden, W. D. J. Biol. Chem. 1992, 267, 18805.
11. Budiman, M. E.; Alexander, R. W.; Bierbach, U. Unique base-step recognition by a platinumacridinylthiourea conjugate leads to a DNA damage profile complementary to that of the anticancer drug cisplatin. Biochemistry 2004, 43, 8560-8567.
12. (a) Mikata, Y.; Mogami, K.; Kato, M.; Okura, L; Yano, S. Synthesis, characterization, interaction with DNA, and antitumor activity of a cis-Dichloroplatinum(II) complex linked to an intercalator via one methylene chain. Bioorg. Med. Chem. Lett. 1997, 7, 1083-1086.
13. (b) Mikata, Y.; Yokoyama, M.; Mogami, K; Kato, M.; Okura, L; Chikira, M.; Yano, S. Intercalator-linked cisplatin: synthesis and antitumor activity of cis-dichloroplatinum(II) complexes connected to acridine and phenylquinolines by one methylene chain. Inorg. Chim. Acta. 1998, 279, 51-57.
14. Holmes, R. J.; McKeage, M. J.; Murray, V.; Denny, W. A.; McFayden, W. D. cis-Dichloroplatinum(II) complexes tethered to 9-aminoacridine-4-carboxamides: synthesis and action in resistant cell lines in vitro. J. Inorg. Biochem. 2001, 85, 209-217.
15. Todd, J. A.; Rendina, L. M. Synthesis and DNA-binding properties of cationic 2,2′:6′,2″-terpyridineplatinum(II) complexes containing 1,2- and 1,7-dicarba-closo-dodecaborane(12). Inorg. Chem. 2002, 41, 3331-3333.
16. (e) Ackley, M. C.; Barry, C. G.; Mounce, A. M.; Farmer, M. C.; Spring, B. E.; Day, C. S.; Wright, M. W.; Berners-Price, S. J.; Hess, S. M.; Bierbach, U. Structure-activity relationships in platinum-acridinylthiourea conjugates: effect of the thiourea nonleaving group on drug stability, nucleobase affinity, and in vitro cytotoxicity. J. Biol. Inorg. Chem. 2004, 9, 453-461.
17. Ferez, J. M.; Lopez-Solera, I; Momtero, E. I; Brara, M. F.; Alonso, C.; Robinson, S. P.; Navarro-Ranninger, C. Combined effect of platination and intercalation upon DNA binding of novel cytotoxic Pt-bis(naphthalimide) complexes. J. Med. Chem. 1999, 42, 5482-5486.
18. 2 complexes linked to anthraquinone intercalators, J. Med. Chem. 1991, 34, 414-420.
19. (b) Gibson, D.; Binyamin, I; Haj, M.; Ringel, I; Ramu, A.; Katzhendler, J. Anthraquinone intercalators as carrier molecules for second-generation platinum anticancer drugs. Eur. J. Med. Chem. 1997, 32, 823-831.
20. (a) Perez, J. M.; Lopez-Solera, I.; Momtero, E. I.; Brara, M. F.; Alonso, C.; Robinson, S. P.; Navarro-Ranninger, C. Combined effect of platination and intercalation upon DNA binding of novel cytotoxic Pt-bis(naphthalimide) complexes. J. Med. Chem. 1999, 42, 5482-5486.
21. (b) Perrin, L. C.; Prenzler, P. D.; Culliname, C.; Phillips, D. R.; McFayden, W. A. DNA targeted platinum complexes: synthesis, cytotoxicity and DNA interactions of cis-dichloroplatinum (II) complexes tethered to phenazine-1-car-boxamides. J. Inorg. Biochem. 2000, 81, 111-117.
22. (a) Baruah, H.; Rector, C. L.; Monnier, S. M.; Bierbach, U. Mechanism of action of non-cisplatin type DNA-targeted platinum anticancer agents: DNA interactions of novel acridinylthioureas and their platinum conjugates. Biochem. Pharmacol. 2002, 64, 191-200.
23. (b) Baruah, H.; Bierbach, U. Unusual intercalation of acridin-9-ylthiourea into the 5′-GAATC DNA base step from the minor groove: implications for the covalent DNA adduct profile of a novel platinum-intercalator conjugate. Nucleic Acids Res. 2003, 31, 4138-4146.
24. Baruah, H.; Day, C. S.; Wright, M. W.; Bierbach, U. Metal-intercalator- mediated self-association and one-dimensional aggregation in the structure of the excised major DNA adduct of a platinum-acridine agent. J. Am. Chem. Soc. 2004, 126, 4492-4493.
25. Whittaker, J.; McFayden, W. D.; Wickham, G.; Wakelin, L. P. G.; Murray, V. The interaction of DNA-targeted platinum phenanthridinium complexes with DNA. Nucleic Acids Res. 1998, 26, 3933-3939.
26. Temple, M. D.; McFayden, W. D.; Holmes, R. J.; Denny, W. A.; Murray, V.; Interaction of Cisplatin and DNA-Targeted 9-Aminoacridine Platinum Complexes with DNA. Biochemistry 2000, 39, 5593-5599.
27. (a) Criado, J. J.; Fernandez, E. R.; Manzano, J. L.; Alonso, A.; Barrena, S.; Medarde, M.; Pelaez, R.; Tabernero, M. D.; Orfao, A. Intrinsically fluorescent cytotoxic cisplatin analogues as DNA marker molecules. Bioconjugate Chem. 2005, 16, 275-282.
28. (b) Molenaar, C.; Teuben, J. M.; Heerebrij, R. B.; Tanke, H. J.; Reedijk, J. J. Biol. Inorg. Chem. 2000, 5, 655-665.
29. (a)Kelland, L. R.; Abel, G.; McKeage, M. J.; Jones, M.; Goddard, P. M.; Valenti, M.; Murrer, B. A.; Harrap, K. R. Preclinical antitumor evaluation of bis-acetato-amine-dichloro-cyclohexyl-amine platinum(IV): an orally active platinum drug. Cancer Res. 1993, 53, 2581-2586.
30. (b) Pors, K.; Paniwnyk, Z.; Ruparelia, K. C.; Teesdale-Spittle, P. H.; Hartley, J. A.; Kelland, L. R.; Patterson, L. H. Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells. J. Med. Chem. 2004, 47, 1856-1859.
31. Behrens, B. C.; Hamilton, T. C.; Masuda, H.; Grotzinger, K. R.; Whang-Peng, J.; Louie, K. G.; Knutsen, T.; McKoy, W. M.; Young, R. C. Ozols, R. F. Characterization of a cis-diaminedi-chloroplatinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 1987, 47, 414-418.
32. (a) Alley, M. C.; Scudiero, D. A.; Monks, P. A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay. Cancer Res. 1988, 48, 589-601,
33. (b) Grever, M. R.; Schepartz, S. A.; Chabner, B. A. The National Cancer Institute: Cancer Drug Discovery and Development Program. Semin. Oncol. 1992, 19 (No. 6), 622-638,
34. Boyd, M. R.; Paull, K. D. Some Practical Considerations and Applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen. Drug Dev. Res. 1995, 34, 91-109.